Patrick Stadler

Much of my work focuses on supporting the development of new vaccines, which (obviously!) matters enormously. But there’s a lot of impact left on the table with vaccines we already have. Important details (dose, schedule, and patient eligibility) are often set during development, and there’s little commercial incentive to revisit them later. Yet the payoff can be huge. For example, the switch to single-dose HPV schedules means a more cost-effective vaccine, and the same vaccine supply protects far more people. So @coeff_giving is launching a $30 million call for work that gets more out of licensed and late-stage vaccines, primarily in low- and middle-income countries. Ideas don’t need to be fully formed. EOIs due Dec 21: coefficientgiving.org/funds/…